Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study

Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for... BackgroundAbiraterone acetate plus prednisone with androgen deprivation therapy is a standard treatment option for patients with high-risk metastatic castration-sensitive prostate cancer (mCSPC). However, no data are available on the optimal subsequent treatment option in patients treated with abiraterone acetate plus prednisone for high-risk mCSPC.ObjectiveWe aimed to compare the clinical outcomes of subsequent therapy after discontinuation of abiraterone acetate plus prednisone in patients with high-risk mCSPC.MethodsOverall survival and time to treatment failure from initiation of subsequent therapies were estimated by applying a marginal structural Cox proportional hazards model using inverse probability of treatment weighting with a change of time scale to time on treatment.ResultsA total of 217 patients received subsequent therapies: 127 received chemotherapy, 49 received non-chemotherapy, and 41 received other treatments. For overall survival, when adjusted with the marginal structural Cox proportional hazards model using inverse probability of treatment weighting, the hazard ratio was 1.212 (95% confidence interval [CI] 0.742–1.979) for chemotherapy versus non-chemotherapy, 0.534 (95% CI 0.267–1.066) for non-chemotherapy versus other treatments, and 0.635 (95% CI 0.317–1.271) for chemotherapy versus other treatments. For time to treatment failure, the hazard ratio was 1.287 (95% CI 0.832–1.989) for chemotherapy versus non-chemotherapy, 0.785 (95% CI 0.486–1.269) for non-chemotherapy versus other treatments, and 0.898 (95% CI 0.612–1.318) for chemotherapy versus other treatments.ConclusionsNo differences were observed between the treatment effects of chemotherapy and non-chemotherapy in patients with high-risk mCSPC after abiraterone acetate plus prednisone. These findings suggest that life-extending subsequent therapy after abiraterone acetate plus prednisone for mCSPC should be chosen at the physician’s discretion and patient’s preference.Clinical Trial RegistrationClinicalTrials.gov, NCT01715285, registered 26 October, 2012. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Targeted Oncology Springer Journals

Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study

Koroki, Yosuke; Taguri, Masataka
Targeted Oncology , Volume 18 (1) – Jan 1, 2023
Download PDF
10 pages

Loading next page...
 
/lp/springer-journals/clinical-outcomes-of-first-subsequent-therapies-after-abiraterone-6htU0rwTA2

References (43)

Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2022
ISSN
1776-2596
eISSN
1776-260X
DOI
10.1007/s11523-022-00929-3
Publisher site
See Article on Publisher Site

Abstract

BackgroundAbiraterone acetate plus prednisone with androgen deprivation therapy is a standard treatment option for patients with high-risk metastatic castration-sensitive prostate cancer (mCSPC). However, no data are available on the optimal subsequent treatment option in patients treated with abiraterone acetate plus prednisone for high-risk mCSPC.ObjectiveWe aimed to compare the clinical outcomes of subsequent therapy after discontinuation of abiraterone acetate plus prednisone in patients with high-risk mCSPC.MethodsOverall survival and time to treatment failure from initiation of subsequent therapies were estimated by applying a marginal structural Cox proportional hazards model using inverse probability of treatment weighting with a change of time scale to time on treatment.ResultsA total of 217 patients received subsequent therapies: 127 received chemotherapy, 49 received non-chemotherapy, and 41 received other treatments. For overall survival, when adjusted with the marginal structural Cox proportional hazards model using inverse probability of treatment weighting, the hazard ratio was 1.212 (95% confidence interval [CI] 0.742–1.979) for chemotherapy versus non-chemotherapy, 0.534 (95% CI 0.267–1.066) for non-chemotherapy versus other treatments, and 0.635 (95% CI 0.317–1.271) for chemotherapy versus other treatments. For time to treatment failure, the hazard ratio was 1.287 (95% CI 0.832–1.989) for chemotherapy versus non-chemotherapy, 0.785 (95% CI 0.486–1.269) for non-chemotherapy versus other treatments, and 0.898 (95% CI 0.612–1.318) for chemotherapy versus other treatments.ConclusionsNo differences were observed between the treatment effects of chemotherapy and non-chemotherapy in patients with high-risk mCSPC after abiraterone acetate plus prednisone. These findings suggest that life-extending subsequent therapy after abiraterone acetate plus prednisone for mCSPC should be chosen at the physician’s discretion and patient’s preference.Clinical Trial RegistrationClinicalTrials.gov, NCT01715285, registered 26 October, 2012.

Journal

Targeted Oncology – Springer Journals

Published: Jan 1, 2023

There are no references for this article.